Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gael Deplanque
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer
JAMA Oncology
Cancer Research
Oncology
Galunisertib Plus Gemcitabine vs. Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
British Journal of Cancer
Cancer Research
Oncology
Related publications
FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer
World Journal of Surgical Oncology
Surgery
Oncology
P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer
Cancer Research and Treatment
Cancer Research
Oncology
PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Continued Cetuximab for Unresectable Metastatic Colorectal Cancer After Disease Progression During First-Line Cetuximab-Based Chemotherapy: A Retrospective Cohort Study
Oncotarget
Oncology
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
Cancers
Cancer Research
Oncology
Impact of Primary Tumour Location on Efficacy of Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Cetuximab in First Line Treatment of Metastatic Colorectal Cancer
Farmeconomia. Health economics and therapeutic pathways
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Is an Independent Prognostic Marker in Wild-Type KRAS Metastatic Colorectal Cancer After Colorectal Liver Metastasectomy
BMC Cancer
Cancer Research
Oncology
Genetics
